hotspot -WSS

hotspot

author：explore 2025-09-27 12:48:09 - browse：62

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Wikipedia

WSS

Kidney transplant patients stopped immunosuppressants in trial

Lung cancer screening guidelines updated for cigarette smokers

'The View' co

After Sarepta trial failure, Duchenne families brace for more debate

Brain injuries and the importance of a second opinion

Coloradans with cystic fibrosis could lose access to Trikafta

focus

hotspot

hotspot

Medical records are filled with copy

Reframing the conversation around gain

Medical records are filled with copy

DeepMind touts AlphaFold's new skills as protein folding AI models face off

DIEP, the 'gold standard' of breast reconstruction, is under threat

Biden White House, tech companies launch new safeguards around emerging AI technology

23andMe had bad news about my health. I wish a person had delivered it

Why the advice to take all your antibiotics may be wrong

BioMarin wins approval for gene therapy to treat hemophilia A

It's time to take a new tack for treating Alzheimer's

explore

Inari Medical to buy amputation prevention company LimFlow

Key Senate panel to consider PBM, drug pricing reform package

Reframing the conversation around gain

It's time to take a new tack for treating Alzheimer's

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

Brain injuries and the importance of a second opinion

knowledge

Wikipedia

hotspot

focus